Benefit seen with additional six weeks of treatment after six weeks of initial failure with varenicline or nicotine replacement
Significant increase seen in monthly number of buprenorphine prescribers, but modest increase seen in number of patients receiving buprenorphine
Although most effective for symptoms, medications are also tied to adverse effects
Single low-dose esketamine reduces depressive episodes at 42 days postpartum for mothers with prenatal depression
Reduction seen in incidence of composite outcome of all-cause mortality, return to hospital with MAUD initiation at discharge
Risk for cardiomyopathy increased with duration of treatment for adults aged 20 to 40 years with ADHD
Reduced risk for psychiatric, nonpsychiatric hospitalization seen with use of ADHD meds among adolescents, adults with ADHD
Significantly lower rates seen for all-cause mortality and unnatural-cause mortality, but not natural-cause mortality
Quit rate higher for ECs than nicotine replacement therapy; at six months, 62.8 percent in EC arm still using ECs
No serious injuries related to the medication mix-up have been reported